| TARGET | |
|---|---|
| SYNONYMS |
TNFRSF17 |
| HOST SPECIES |
Rabbit |
| DESCRIPTION |
Anti-BCMA bispecific antibody(DM16) |
| DELIVERY |
In Stock |
| UNIPROT ID |
Q02223 |
| IGG TYPE |
Rabbit scfv |
| CLONALITY |
Monoclonal |
| REACTIVITY |
Human |
| APPLICATIONS |
Flow Cyt; MM Tumor cell killing |
| RECOMMENDED DILUTIONS |
Flow Cyt 1:100; MMTumor cell killing |
| PURIFICATION |
Purified from cell culture supernatant by affinity chromatography |
| FORMULATION & RECONSTITUTION |
Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| STORAGE & SHIPPING |
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| BACKGROUND |
BiTE bispecific antibody is an Engineered fusion protein constructed from two single-chain variable fragments (scFvs) of different monoclonal antibodies. One of the scFvs will be constructed from an anti-CD3 monoclonal antibody; and the other scFv fragment which linked by a linker region will be made from an anti-Tumor cell specific monoclonal antibody.The B-cell maturation protein (BCMA or BCM) is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes; and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily; member 13b (TNFSF13B:TALL-1:BAFF); and to lead to NF-kappaB and MAPK8:JNK activation. This receptor also binds to various TRAF family members; and thus may transduce signals for cell survival and proliferation. [provided by RefSeq; Jul 2008] |
| USAGE |
Research use only |
Dima Biotech
SKU(재고 관리 코드):DMB100005
Anti-BCMA bispecific antibody(DM16)
Anti-BCMA bispecific antibody(DM16)
PRODUCT DATA
IMAGES
Figure 1. The basic principle of BiTE cell killing assay. The BiTE molecule can effectively bring T cells to tumor target cells and stimulate tumor cell killing activity of T cells.
Figure 2. A: The scheme of Anti-BCMA BiTE molecule. B: Tumor cell killing assay. NCI-H929 cells (stably transfected with luciferase), were incubated with freshly isolated human PBMC, and different concentration of BiTE antibodies constructed from rabbit Anti-Human BCMA/TNFRSF17 Clone DM16 (red line), or BB2121 originated huC11D5.3 clone (blue line) or a no BCMA binding clone as negative control (black line). After 48hrs incubation, the viable NCI-H929 tumor cells were measured by luciferase activity assay.
